1-(3,3-Dimethyl-2-oxobutyl)pyrrolidine-2,5-dione | 1247386-12-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(3,3-Dimethyl-2-oxobutyl)pyrrolidine-2,5-dione
• CAS: 1247386-12-4
• 化学式: C₁₀H₁₅NO₃
• mdl: MFCD16040365
• 分子量: 197.234
• InChiKey: XFKBTOXQBLLEQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-(3,3-Dimethylbut-1-ynyl)pyrrolidine-2,5-dione 在 silver tetrafluoroborate 、 三苯基膦双(三氟甲磺酰亚胺)金 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以88%的产率得到1-(3,3-Dimethyl-2-oxobutyl)pyrrolidine-2,5-dione
  参考文献：
  名称：

  Ag和Au催化的醇加到Ynimides上：β-区域选择性羰基化和恶唑的生产

  摘要：

  证明了酰亚胺与醇的金属催化反应，得到β-酮酰亚胺和恶唑。乙酰胺的三键通常被无机酸或金属盐激活，从而由于固有的电子偏压而导致亲核试剂在α-C原子上的区域选择性加成。相反，酰亚胺的两个相邻的羰基降低了三键的电子密度，亲核试剂攻击了羰基C原子。

  DOI：

  10.1021/ol400338x

文献信息

• TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS
  申请人：David Sunil A.

  公开号：US20120294885A1

  公开（公告）日：2012-11-22

  The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure.

  本公开提供了新型咪唑喹啉衍生化合物，其衍生物，类似物，以及其药用盐，并提供了制备和使用这些化合物的方法。本公开还提供了TLR7激动剂和TLR7/TLR8双激动剂，探针，组织特异性分子，佐剂，免疫原性组合物，治疗组合物，以及包括咪唑喹啉衍生化合物，其衍生物，类似物和药用盐的自佐剂疫苗。咪唑喹啉衍生化合物的衍生物还包括咪唑喹啉衍生化合物的树枝状分子和二聚体，以及制备和使用这些树枝状和二聚体咪唑喹啉衍生化合物的方法。本公开还提供了包括本公开的咪唑喹啉衍生化合物的双TLR2/TLR7混合激动剂。
• Hypoiodite‐Catalyzed Oxidative α‐C−N Coupling of Ketones with Imides and Azoles
  作者：Mayuko Tsukahara、Muhammet Uyanik、Kazuaki Ishihara

  DOI：10.1002/adsc.202300716

  日期：2023.8.15

  Herein, we report a direct method for the synthesis of α-imidoketones and α-azolylketones via hypoiodite-catalyzed oxidative α-C−N coupling of ketones with the corresponding imides and azoles, respectively. The use of inorganic base additives such as cesium carbonate in the presence of 18-crown-6 as a phase transfer catalyst was crucial to induce high reactivity. Control experiments revealed that the

  在此，我们报道了一种通过次碘酸盐催化酮与相应酰亚​​胺和唑的氧化 α-C−N 偶联直接合成 α-亚胺酮和 α-唑基酮的方法。在 18-crown-6 存在下使用碳酸铯等无机碱添加剂作为相转移催化剂对于诱导高反应性至关重要。对照实验表明，碱性添加剂不仅可能促进高周转次碘酸盐催化，而且还参与偶联配偶体的活化。
• US20140256922A1
  申请人：——

  公开号：US20140256922A1

  公开（公告）日：2014-09-11
• Compounds and Compositions for Immunotherapy
  申请人：SHANGHAI BIRDIE BIOTECH, INC.

  公开号：US20160324983A1

  公开（公告）日：2016-11-10

  Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of diseases such as cancer. Also provided are compositions comprising the compounds.
• Compounds and Compositions for Treating HER2 Positive Tumors
  申请人：SHANGHAI BIRDIE BIOTECH, INC.

  公开号：US20170028079A1

  公开（公告）日：2017-02-02

  Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of HER2 positive tumors/cancers. Also provided are compositions comprising the compounds.